Effects of Treatment With Cyclosporine Ophthalmic Solution 0.09% on Dry Eye Questionnaire Scores Among Patients With Dry Eye Disease.

Objective This multicenter, retrospective study was conducted to evaluate patient-reported scores for the 5-part Dry Eye Questionnaire (DEQ-5) over a six-month treatment period using cyclosporine ophthalmic solution 0.09% (CsA 0.09%). Materials and methods Patients with moderate-to-severe dry eye disease (DED) who completed the DEQ-5 at baseline and at least one post-baseline assessment after one, three, and six months of twice-daily CsA 0.09% treatment were included in the study. Adverse events were recorded. Results A total of 392 patients entered the study. At baseline, the mean (standard deviation (SD)) DEQ-5 score was 14.7 (3.4). The scores improved to 12.6 (4.1), 11.9 (4.2), and 10.8 (4.4) at one, three, and six months, respectively, corresponding with reduced DED symptoms. Most patients reported improvements in DEQ-5 scores at each time point; by month six, 69/88 (78.4%) patients reported improved DEQ-5 scores from baseline, while 8/88 (9.1%) reported no changes and 11/88 (12.5%) reported progression of DED symptoms. Conclusions CsA 0.09% was well tolerated and led to significant improvements in DEQ-5 scores, reflecting better management of DED symptoms at one, three, and six months of treatment. These results highlight the potential of CsA 0.09% as a long-term treatment option for moderate to severe DED.